Aizon's GxP AI platform on AWS identified drivers of lost yield in plasma drug production.
Yield had dropped unexplained and process variability grew for years, while data scientists spent about 80% of their time cleaning data. Aizon built a GxP-compliant AI platform on AWS Lambda, SageMaker and IoT connected to bioreactors. The page states plasma composition origin explained over 50% of variance, two critical variables were found, yield improved by double digits and compute costs fell up to 80%.
Aizon is an AI platform company whose GxP-compliant software analyses bioprocess data to improve yield and reduce deviations in pharma manufacturing
This sits in the Build stage of the AI use-case lifecycle: Named examples from the foundation-model labs and platforms pharma teams use to actually construct, train and generate the model or application.
Published by Aizon on its own site — read the original case study on aws.amazon.com ↗
Note: Story is hosted on the AWS case-study site.
Related use cases
- 01OpenAI's dedicated healthcare vertical page/launch post.
- 02Frontier reasoning model built for biology, drug discovery and translational medicine; named qualified customers include Amgen, Moderna, Allen Institute, and Thermo Fisher Scientific.
- 03follow-up update to the life-sciences model.
- 04"How Amgen uses GPT-5": Amgen applies GPT-5/frontier models to help accelerate delivery of potential new therapies; found GPT-5 met scientific-accuracy standards.
- 05Moderna and OpenAI partner to accelerate development of treatments; ChatGPT Enterprise deployed to thousands of employees company-wide.
- 06Longevity biotech collaborated with OpenAI to build and research GPT-4b micro, a version of GPT-4o specialized for protein engineering.